14.56
+0.02
+(0.14%)
At close: January 31 at 4:25:00 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
108,191.00
118,939.00
136,971.00
127,970.00
93,449.00
Cost of Revenue
6,498.00
5,926.00
5,180.00
3,885.00
1,131.00
Gross Profit
101,693.00
113,013.00
131,791.00
124,085.00
92,318.00
Operating Expense
103,180.00
97,266.00
95,317.00
65,653.00
49,524.00
Operating Income
-1,487.00
15,747.00
36,474.00
58,432.00
42,794.00
Net Non Operating Interest Income Expense
8,247.00
7,633.00
4,138.00
-134.00
-362.00
Pretax Income
8,145.00
24,765.00
42,142.00
59,002.00
42,409.00
Tax Provision
3,517.00
5,340.00
9,283.00
12,621.00
-33,143.00
Net Income Common Stockholders
4,628.00
19,425.00
32,860.00
46,380.00
83,119.00
Diluted NI Available to Com Stockholders
4,628.00
19,425.00
32,860.00
46,380.00
83,119.00
Basic EPS
0.08
0.38
0.65
0.94
1.76
Diluted EPS
0.08
0.38
0.65
0.93
1.73
Basic Average Shares
53,196.83
50,709.00
50,413.00
49,338.00
48,335.00
Diluted Average Shares
53,328.83
50,841.00
50,928.00
50,053.00
49,119.00
Total Operating Income as Reported
-1,488.00
15,746.00
36,474.00
58,432.00
42,793.00
Rent Expense Supplemental
4,109.00
--
--
--
2,880.00
Total Expenses
109,678.00
103,192.00
100,497.00
69,538.00
50,655.00
Net Income from Continuing & Discontinued Operation
4,628.00
19,425.00
32,860.00
46,380.00
83,119.00
Normalized Income
3,219.32
18,008.42
33,074.42
46,357.20
73,763.00
Interest Income
450.00
8,131.00
3,386.00
841.00
349.00
Interest Expense
797.00
498.00
684.00
694.00
631.00
Net Interest Income
8,247.00
7,633.00
4,138.00
-134.00
-362.00
EBIT
8,029.00
25,263.00
42,826.00
59,696.00
43,040.00
EBITDA
14,014.00
31,644.00
47,847.00
62,887.00
52,994.00
Reconciled Cost of Revenue
6,498.00
5,926.00
5,180.00
3,885.00
1,131.00
Reconciled Depreciation
5,985.00
6,381.00
5,021.00
3,191.00
9,954.00
Net Income from Continuing Operation Net Minority Interest
4,628.00
19,425.00
32,860.00
46,380.00
73,763.00
Total Unusual Items Excluding Goodwill
1,806.00
1,806.00
-275.00
29.00
--
Total Unusual Items
1,806.00
1,806.00
-275.00
29.00
--
Normalized EBITDA
12,208.00
29,838.00
48,122.00
62,858.00
52,994.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
397.32
389.42
-60.58
6.20
--
12/31/2020 - 11/4/2005
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
CLBIO.ST Corline Biomedical AB
9.42
+1.73%
PCIB.OL PCI Biotech Holding ASA
1.2500
+2.12%
DIABIO.ST Diagonal Bio AB (publ)
0.0189
-5.50%
NYKD.OL Nykode Therapeutics AS
2.6820
+1.98%
OTLC Oncotelic Therapeutics, Inc.
0.0303
+8.21%
ACE.ST Ascelia Pharma AB (publ)
2.9150
+1.92%
CAMX.ST Camurus AB (publ)
596.00
-0.17%
EXPRS2.ST ExpreS2ion Biotech Holding AB (publ)
30.60
+2.00%
NAMS NewAmsterdam Pharma Company N.V.
22.29
+2.39%
APRE Aprea Therapeutics, Inc.
3.9100
+0.51%